Challenges to equitable access to medicines

June 11, 2014, University of Auckland

(Medical Xpress)—Access to medicines by vulnerable groups in the community, increasing medicine costs, and the demand for new medicines are some of the challenges identified in an independent study of priority medicine policy issues in New Zealand.

The study, led by Dr Zaheer-Ud-Din Babar from the University of Auckland's School of Pharmacy, also identified issues with access to prescribers, budgetary constraints, cultural and health literacy, patient medicine affordability and the evidence required for gaining subsidy for medicines.

These findings come from the first independent study to identify medicine policy issues in New Zealand. The study consulted 20 stakeholder groups from a broad range of healthcare and policy institutions.

"While overall there was reasonable satisfaction with the availability of subsidised medicines, there were some major challenges", says Dr Babar.

"In the context of PHARMAC's fixed budget for procuring and subsidising medicines, there was reasonable satisfaction with the range of medicines available—rare disorder medicines being the clear exception," he says. "There were concerns raised about the decision making process and whether desired health outcomes are being measured."

"Despite attempts to improve the situation, there are challenges of access to medicines for people in lower socio-economic groups, Māori and Pacific Island people and those with rare disorders," says Dr Babar.

Other barriers to access to medicines included convenience to and affordability of prescribers, and the increase of prescription fees from NZ$3 to NZ$5.

"The study shows that low socio-economic groups, (encompassing Māori and Pacifica people) were continuing to have access issues related to financial, structural, educational and cultural barriers," he says.

Concerns relating to PHARMAC included budget constraints, a lack of transparency of in-house analysis, and a lack of consistency in recommendations between the Pharmacology and Therapeutics Advisory Committees.

"Constraints and inefficiencies also exist in the submission process to access high-cost medicines," says Dr Babar.

The study identified many of the reservations held by healthcare groups about the Trans Pacific Partnership Agreement (TPPA) and its impact on Pharmac and the availability of high cost medicines.

"There was concern from stakeholders that already 'big amounts' are being spent on healthcare and the 'benefits are low' and if there was a resultant increase in the cost of medicines, where the resources would come from to offset any cost increases," he says.

"Very few participants were familiar with the TPPA," says Dr Babar. "There was scepticism voiced about the driving force behind the agreement and what the benefits would be for NZ when the USA was a heavily subsidised protected market."

"Most participants considered that New Zealand's ability to access or independence in procuring medicines should be upheld," says Dr Babar. "If not, funds may need to be redirected from other services, or patient co-payments would need to rise, to compensate a likely increase in the cost of medicines."

Explore further: Asthma medicines a struggle for many countries

More information: The study is available online: bmjopen.bmj.com/content/4/5/e004415.full

Related Stories

Asthma medicines a struggle for many countries

October 16, 2013
(Medical Xpress)—The availability, pricing and affordability of three essential asthma medicines varies greatly according to a new study of 52 low-and middle-income countries

Kiwis missing out on free prescription medicines entitlement

November 13, 2012
Many New Zealanders are not getting free prescriptions when they should and these people are likely to include our most vulnerable, new findings from an ongoing University of Otago and Victoria University study into equity ...

Global recommendations on child medicine

May 21, 2013
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

How health systems factors affect access to psychotropic medicines

January 31, 2012
In a cross-sectional analysis of WHO-AIMS data published in this week's PLoS Medicine, Ryan McBain of Harvard School of Public Health, Boston, USA and colleagues investigated the associations between health system components ...

New dysphagia and medicines resource now live

May 1, 2013
Healthcare professionals caring for patients with dysphagia (swallowing difficulties) now have access to a new and comprehensive online resource called 'Medicines Optimisation in Patients with Dysphagia' (www.dysphagia-‐medicine.com/).

Recommended for you

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.